26 results about "Refractory cancer" patented technology

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.

An embodiment of the present invention relates to: a cancer antigen peptide nanostructure comprising an assembly of cancer antigen peptides conjugated with deoxycholic acid; a method for preparing same; and use thereof. The inventors of the present invention confirmed that the nanostructure of the present invention effectively stimulates the maturation of dendritic cells, migrates to lymph nodes, and activates T cells. Also, in a cancer cell model, significant infiltration of cytotoxic T lymphocytes into primary tumors was observed, and an anti-metastatic effect was confirmed. Therefore, the nanostructure according to the present invention can be effectively used as a promising immunotherapy platform that can be applied to various intractable cancers.

The present invention relates to an anti-PTK7 antibody and a use thereof. The anti-PTK7 antibody according to the present invention was found to inhibit angiogenesis, as well as the growth, migration, and invasion of human umbilical vein endothelial cells (HUVECs). Additionally, it effectively suppresses tumor growth in vivo, making it a promising therapeutic agent for angiogenesis-related diseases and PTK7-positive cancers. The antibody also has potential for further development as a targeted therapy for intractable cancers, positioning it as a key global therapeutic agent. Furthermore, the antibody can be humanized for clinical applications and serve as a critical component in the development of novel therapeutics.

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof, for use in the treatment of cancer in a patient, wherein the cancer is a refractory cancer which shows resistance to treatment with a topoisomerase inhibitor and / or a tubulin inhibitor.

The present invention discloses a method for treating cancer in a subject by administering a pharmaceutical composition comprising a compound of Formula (I) or its salt, co-crystal, or solvate. The disclosed method offers a promising approach to treat cancers including recalcitrant cancers, thereby providing a valuable contribution to the field of oncology.

Invention relates to new platinum (IV) complexes with substantially increased antitumor efficacy; a process for preparing these new platinum (IV) complexes; a pharmaceutical composition and a final dosage form for oral administration of the new platinum (IV) complexes; and the use of the new platinum (IV) complex in a method to treat a tumor disease, preferably a heavy-to-treat cancer, most preferably pancreatic cancer, preferably by oral administration.

Provided herein is method of treating a refractory cancer comprising administering to a subject in need thereof a conjugate of Formula (XX) or a pharmaceutically acceptable salt thereof, wherein L is a Targeting Unit and the rest of the variables of Formula (XX) are as defined in the application. Such compounds can be useful as anti-cancer agents.

The present invention provides a pharmaceutical composition for the treatment of cancer having KRAS variant genotype or PTEN protein loss genotype, comprising an anti-cancer chemotherapeutic prodrug conjugate consisting of an albumin binding moiety, a linker, and an anti-cancer chemotherapeutic agent, for the effective treatment of cancers having KRAS variant genotype or PTEN protein loss genotype, which are known to be refractory cancers.

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof, for use in the treatment of cancer in a patient, wherein the cancer is a refractory cancer which shows resistance to treatment with a topoisomerase inhibitor and / or a tubulin inhibitor.

Disclosed herein are compositions and methods for deploying interventional agents into constrained biological states using non-crystalline amorphous iron oxide nanoparticles (NAIONPs). The NAIONPs comprise coordination-stabilized, aqueous colloidal dispersions lacking long-range crystalline order and presenting surface-accessible coordination sites for reversible or covalent association with one or more interventional agents. The compositions are configured to modify the biological context in which an interventional agent is presented, enabling functional engagement of agents whose deployment is limited when administered in isolation due to factors including impaired biodistribution, reduced stability, stress sensitivity, immune-mediated clearance, altered cellular responsiveness, or non-optimal exposure conditions. Interventional agents may include polynucleotides, peptides, proteins, small molecules, targeting moieties, radiologic agents, or combinations thereof. The disclosed compositions and methods are applicable to in vivo, ex vivo, and in vitro biological systems, including oncologic disease states such as primary tumors, metastatic disease, hematologic malignancies, and treatment-refractory cancers.

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof, for use in the treatment of cancer in a patient, wherein the cancer is a refractory cancer which shows resistance to treatment with a topoisomerase inhibitor and / or a tubulin inhibitor.

The present invention relates to a therapeutic target for stem-like, epithelial-to-mesenchymal transition and mesenchymal (SEM) cancer subunits and an inhibitor thereof. In the present invention, on the basis of the fact that the intracellular concentration of ATP is high in SEM cancer subunits, a preparation for the prevention or treatment of gastric cancer can be effectively screened for by measuring the mRNA level of a gene encoding an ATP affinity protein or the expression level of the ATP affinity protein, information for predicting and diagnosing gastric cancer can be provided, a kit for diagnosing gastric cancer or predicting the prognosis thereof is provided, and a composition for diagnosing gastric cancer or predicting the prognosis thereof can be effectively provided.

The present invention relates to a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and / or relapsed cancer. The invention also relates to a method of treating refractory cancer and / or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

The use of a pharmaceutical composition in treating cancer in a subject comprising a therapeutically effective amount of a compound of formula (I), a therapeutically effective amount of paclitaxel and a low dose of gemcitabine, and a kit included above composition thereof.

[Problem]The therapy method and the therapy apparatus for difficult cancer such as ductal cancer and other diseases.[Solution to Problem]The therapy and the apparatus to beat cancer and other diseases by injecting the material which is energy receptive from outside and emissive heat to cancer cells in the body of a patient, and giving energy from outside.

Provided herein are methods for identifying patient having treatment resistant cancers, such as HPV-related cancers. Therapeutic methods for treatment of cancers are also provided.

The present invention relates to a structure for surface-enhanced Raman scattering spectroscopy, a method for manufacturing the same, and a diagnostic method using the same. According to the structure for surface-enhanced Raman scattering spectroscopy, the method for manufacturing the same, and the diagnostic method using the same of the present invention, it is possible to provide a structure for surface-enhanced Raman scattering spectroscopy, which can be used as a surface-enhanced Raman scattering spectroscopy, even if there is no biomarker having excellent diagnostic performance in blood indexes. A structure for surface-enhanced Raman scattering spectroscopy, which can be used even for intractable cancers such as pancreatic cancer and intractable diseases, and a method for producing the same. Further, a diagnostic method and a diagnostic system using a surface-enhanced Raman scattering spectrum can be provided by the structure for the surface-enhanced Raman scattering spectrum.

The present disclosure relates to a structure for surface-enhanced Raman scattering spectroscopy, a method of preparing the same, and a diagnostic method using the same. According to the structure for surface-enhanced Raman scattering spectroscopy, the method of preparing the same, and the diagnostic method using the same, of the present disclosure, a structure for surface-enhanced Raman scattering spectroscopy and a method of preparing the same may be provided, which can be used even when biomarkers with excellent diagnostic performance among blood indicators do not exist, as in the case of intractable cancer, such as pancreatic cancer, and intractable diseases. Also, a diagnostic method and diagnostic system using surface-enhanced Raman scattering spectroscopy may be provided by using the structure for surface-enhanced Raman scattering spectroscopy.

Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and / or relapsed cancer, and of a method of treating refractory cancer and / or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

The present disclosure provides methods for treating cancer (e.g., immunorefractory cancer) using RAS inhibitors. The present disclosure also provides combination therapies containing one or more RAS inhibitors for the treatment of cancer.

The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, or a salt thereof, for use in the treatment of cancer in a patient, wherein the cancer is a refractory cancer which shows resistance to treatment with a topoisomerase inhibitor and / or a tubulin inhibitor.

Provided herein is method of treating a refractory cancer comprising administering to a subject in need thereof a conjugate of Formula (XX) or a pharmaceutically acceptable salt thereof, wherein L is a Targeting Unit and the rest of the variables of Formula (XX) are as defined in the application. Such compounds can be useful as anti-cancer agents.

This disclosure concerns methods for predicting treatment outcome to a cancer therapy (in particular combination therapy with CHOP or R-CHOP) by detecting the level of macrophage immunometabolism regulator (MACIR) expression in a subject, wherein an increased MACIR expression indicates likely non-responsiveness to the cancer therapy. Also provided are methods of treating refractory cancer using MACIR inhibitors.

The present invention relates to a method for the prevention, improvement, or treatment of cancer patients, particularly patients with EMT (Epithelial mesenchymal transition) subtype cancer. In cancer patients in whom the expression level of the GLS (Glutaminase) gene or the protein encoded by it is increased, when PHGDH, SHMT, and MTHFD2 inhibitors are administered in combination, 1C metabolism is more effectively inhibited, and there is a synergistic effect in inhibiting the proliferation of cancer cells in patients with intractable cancer that is difficult to treat due to recurrence, metastasis, and resistance to anticancer drugs, thereby enabling very effective treatment of cancer. Furthermore, by measuring the expression levels of the GLS gene or the protein encoded by it, information regarding personalized treatment methods can be provided to individual patients from the early stages, thereby increasing the success rate of treatment.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.